Stefanos Zafeiropoulos, Umair Ahmed, Alexandra Bekiaridou, Naveen Jayaprakash, Ibrahim T Mughrabi, Nafiseh Saleknezhad, Chrystal Chadwick, Anna Daytz, Izumi Kurata-Sato, Yemil Atish-Fregoso, Kaitlin Carroll, Yousef Al-Abed, Marat Fudim, Christopher Puleo, George Giannakoulas, Mark Nicolls, Betty Diamond, Stavros Zanos
BACKGROUND: Inflammation is pathogenically implicated in pulmonary arterial hypertension; however, it has not been adequately targeted therapeutically. We investigated whether neuromodulation of an anti-inflammatory neuroimmune pathway involving the splenic nerve using noninvasive, focused ultrasound stimulation of the spleen (sFUS) can improve experimental pulmonary hypertension. METHODS: Pulmonary hypertension was induced in rats either by Sugen 5416 (20 mg/kg SQ) injection, followed by 21 (or 35) days of hypoxia (sugen/hypoxia model), or by monocrotaline (60 mg/kg IP) injection (monocrotaline model)...
May 7, 2024: Circulation Research